干細胞治療急性呼吸窘迫綜合征及提高療效的相關研究進展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

那仁格日勒 ^1,2 , 阿拉坦高勒 ² ,  安彩艷 ³ ,  楊敬平 ¹

1. ;
2. ;
3. ;

Corresponding?author：

安彩艷, Email: acy_1999@163.com; 楊敬平, Email: yangron@sina.com.cn

Keywords：

DOI：

10.7507/1671-6205.201801006

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 那仁格日勒, 阿拉坦高勒, 安彩艷, 楊敬平. 干細胞治療急性呼吸窘迫綜合征及提高療效的相關研究進展. Chinese Journal of Respiratory and Critical Care Medicine, 2020, 19(5): 528-532. doi: 10.7507/1671-6205.201801006 Copy

1.	Young L, O'Sullivan F. Acute respiratory distress syndrome. Anaesth Intens Care Med, 2016, 17(10): 526-528.
2.	Horie S, Laffey JG. Recent insights: mesenchymal stromal/stem cell therapy for acute respiratory distress syndrome. F1000research, 2016, 5: 1532.
3.	Matthay MA, Mcauley DF, Ware LB. Clinical trials in acute respiratory distress syndrome: challenges and opportunities. Lancet Respir Med, 2017, 5(6): 524-534.
4.	Yang C, Jiang J, Yang X, et al. Stem/progenitor cells in endogenous repairing responses: new toolbox for the treatment of acute lung injury. J Transl Med, 2016, 14(1): 47.
5.	Li N, Yan YL, Fu S, et al. Lysophosphatidic acid enhances human umbilical cord mesenchymal stem cell viability without differentiation via LPA receptor mediating manner. Apoptosis, 2017, (7): 1-14.
6.	Butler J, Epstein SE, Greene SJ, et al. Intravenous allogeneic mesenchymal stem cells for non-ischemic cardiomyopathy: safety and efficacy results of a phaseⅡ-a randomized trial. Circ Res, 2017, 120(2): 332-340.
7.	Laffey JG, Matthay MA. Fifty years of research in ARDS. Cell-based therapy for acute respiratory distress syndrome. Biology and potential therapeutic value. Am J Respir Crit Care Med, 2017, 196(3): 266-273.
8.	Matthay MA, Zemans RL, Zimmerman GA, et al. Acute respiratory distress syndrome. Nat Rev Dis Pri, 2019, 5: 18.
9.	Fan E, Brodie D, Slutsky AS. Acute respiratory distress syndrome: advances in diagnosis and treatment. JAMA, 2018, 319(7): 698-710.
10.	Standiford TJ, Ward PA. Therapeutic targeting of acute lung injury and acute respiratory distress syndrome. Transl Res, 2016, 167(1): 183-191.
11.	Shi C, Cao X, Chen X, et al. Intracellular surface-enhanced Raman scattering probes based on TAT peptide-conjugated Au nanostars for distinguishing the differentiation of lung resident mesenchymal stem cells. Biomaterials, 2015, 58: 10-25.
12.	Monsel A, Zhu YG, Gudapati V, et al. Mesenchymal stem cell derived secretome and extracellular vesicles for acute lung injury and other inflammatory lung diseases. Expert Opin Biol Ther, 2016, 16(7): 859-871.
13.	Zhao R, Su Z, Wu J, et al. Serious adverse events of cell therapy for respiratory diseases: a systematic review and meta-analysis. Oncotarget, 2017, 8(18): 30511-30523.
14.	Madl CM, Heilshorn SC, Blau HM. Bioengineering strategies to accelerate stem cell therapeutics. Nature, 2018, 557: 335-342.
15.	Qin H, Zhao A. Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics. Protein Cell, 2020: 1-16.
16.	Rojas M, Xu J, Woods CR, et al. Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol, 2005, 33(2): 145-152.
17.	Barui A, Chowdhury F, Pandit A, et al. Rerouting mesenchymal stem cell trajectory towards epithelial lineage by engineering cellular niche. Biomaterials, 2018, 156: 28-44.
18.	Zhao Y, Yang C, Wang H, et al. Therapeutic effects of bone marrow-derived mesenchymal stem cells on pulmonary impact injury complicated with endotoxemia in rats. Int Immunopharmacol, 2013, 15(2): 246-253.
19.	Deng HM, Wu LM, Liu MY, et al. Bone Marrow Mesenchymal Stem Cell-Derived Exosomes Attenuate LPS-Induced ARDS by Modulating Macrophage Polarization Through Inhibiting Glycolysis in Macrophages. Shock, 2020.
20.	Cai DS, Zhou H, Liu WW, et al. Protective effects of bone marrow-derived endothelial progenitor cells and Houttuynia cordata in lipopolysaccharide-induced acute lung injury in rats. Cell Physiol Biochem, 2013, 32(6): 1577-1586.
21.	Xu X, Yang J, Li N, et al. Role of endothelial progenitor cell transplantation in rats with sepsis. Transplant Proc, 2015, 47(10): 2991-3001.
22.	Qi Y, Qian L, Sun B, et al. Mobilization of endothelial progenitor cells from bone marrow is impaired in a piglet model of acute respiratory distress syndrome. Pediatr Crit Care Med, 2013, 14: e233-e242.
23.	Zhou Y, Li P, Goodwin AJ, et al. Exosomes from endothelial progenitor cells improve outcomes of the lipopolysaccharide-induced acute lung injury. Crit Care, 2019, 23: 44.
24.	Abe S, Boyer C, Liu X, et al. Cells derived from the circulation contribute to the repair of lung injury. Am J Respir Crit Care Med, 2004, 170(11): 1158-1163.
25.	Zheng G, Huang L, Tong H, et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir Res, 2014, 15(1): 39.
26.	Gupta K, Hergrueter A, Owen CA. Adipose-derived stem cells weigh in as novel therapeutics for acute lung injury. Stem Cell Res Ther, 2013, 4(1): 19.
27.	Bacakova L, Zarubova J, Travnickova M, et al. Stem cells: their source, potency and use in regenerative therapies with focus on adipose-derived stem cells - a review. Biotechnol Adv, 2018, 36: 1111-1126.
28.	Toya SP, Li F, Bonini MG, et al. Interaction of a specific population of human embryonic stem cell-derived progenitor cells with CD11b+ cells ameliorates sepsis-induced lung inflammatory injury. Am J Pathol, 2011, 178(1): 313-324.
29.	Sun N, Panetta NJ, Gupta DM, et al. Feeder-free derivation of induced pluripotent stem cells from adult human adipose stem cells. Proc Natl Acad Sci USA, 2009, 106(37): 15720-15725.
30.	Zhou Q, Ye X, Sun R, et al. Differentiation of mouse induced pluripotent stem cells into alveolar epithelial cells in vitro for use in vivo. Stem Cells Transl Med, 2014, 3(6): 675-685.
31.	那仁格日勒. 內皮祖細胞治療急性呼吸窘迫綜合癥大鼠中溶血磷脂酸的增效作用及其機理[D].內蒙古大學, 2017.
32.	Tavakol DN, Tratwal J, Bonini F, et al. Injectable, scalable 3D tissue-engineered model of marrow hematopoiesis. Biomaterials, 2020, 232: 119665.
33.	He HL, Liu L, Chen QH, et al. MSCs modified with ACE2 restore endothelial function following LPS challenge by inhibiting the activation of RAS. J Cell Physiol, 2015, 230(3): 691-701.
34.	Xu XP, Huang LL, Hu SL, et al. Genetic modification of mesenchymal stem cells overexpressing angiotensin Ⅱ type 2 receptor increases cell migration to injured lung in LPS-induced acute lung injury mice. Stem Cells Transl Med, 2018, 7(10): 721-730.
35.	Fang M, Gao F, Qian LI, et al. Therapeutic effect of human umbilical cord mesenchymal stem cells modified by angiotensin-converting enzyme 2 gene on bleomycin-induced lung fibrosis injury. Mol Med Rep, 2015, 11(4): 2387-2396.
36.	Martínezgonzález I, Roca O, Masclans JR, et al. Human mesenchymal stem cells overexpressing the IL-33 antagonist soluble IL-1 receptor-like-1 attenuate endotoxin-induced acute lung injury. Am J Respir Cell Mol Biol, 2013, 49(4): 552-562.
37.	Chang Y, Park SH, Huh JW, et al. Intratracheal administration of umbilical cord blood-derived mesenchymal stem cells in a patient with acute respiratory distress syndrome. J Korean Med Sci, 2014, 29(3): 438-440.
38.	Galstyan GM, Makarova PM, Parovichnikova EN. Use of mesenchymal stromal stem cells for the treatment of sepsis. Anesteziol Reanimatol, 2015, 60: 59-65.
39.	Simonson OE, Mougiakakos D, Heldring N, et al. In vivo effects of mesenchymal stromal cells in two patients with severe acute respiratory distress syndrome. Stem Cells Transl Med, 2015, 4(10): 1199-1213.
40.	Wilson JG, Liu KD, Zhuo HJ, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med, 2015, 3(1): 24-32.
41.	Matthay MA, Calfee CS, Zhuo H, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med, 2019, 7(2): 154-162.
42.	Chen J, Hu C, Chen L, et al. Clinical Study of Mesenchymal Stem Cell Treatment for Acute Respiratory Distress Syndrome Induced by Epidemic Influenza A (H7N9) Infection: A Hint for COVID-19 Treatment. Engineering(Beijing), 2020, Feb 28. doi: 10.1016/j.eng.2020.02.006. Online ahead of print.
43.	Atluri S, Manchikanti L, Hirsch JA. Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically ill COVID-19 patients: the case for compassionate use. Pain Physician, 2020, 23: E71-E83.
44.	Liang B, Chen J, Li T, et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: a case report. Medicine (Baltimore), 2020, 99: e21429.
45.	Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2 mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis, 2020, 11: 216-228.

1. Young L, O'Sullivan F. Acute respiratory distress syndrome. Anaesth Intens Care Med, 2016, 17(10): 526-528.
2. Horie S, Laffey JG. Recent insights: mesenchymal stromal/stem cell therapy for acute respiratory distress syndrome. F1000research, 2016, 5: 1532.
3. Matthay MA, Mcauley DF, Ware LB. Clinical trials in acute respiratory distress syndrome: challenges and opportunities. Lancet Respir Med, 2017, 5(6): 524-534.
4. Yang C, Jiang J, Yang X, et al. Stem/progenitor cells in endogenous repairing responses: new toolbox for the treatment of acute lung injury. J Transl Med, 2016, 14(1): 47.
5. Li N, Yan YL, Fu S, et al. Lysophosphatidic acid enhances human umbilical cord mesenchymal stem cell viability without differentiation via LPA receptor mediating manner. Apoptosis, 2017, (7): 1-14.
6. Butler J, Epstein SE, Greene SJ, et al. Intravenous allogeneic mesenchymal stem cells for non-ischemic cardiomyopathy: safety and efficacy results of a phaseⅡ-a randomized trial. Circ Res, 2017, 120(2): 332-340.
7. Laffey JG, Matthay MA. Fifty years of research in ARDS. Cell-based therapy for acute respiratory distress syndrome. Biology and potential therapeutic value. Am J Respir Crit Care Med, 2017, 196(3): 266-273.
8. Matthay MA, Zemans RL, Zimmerman GA, et al. Acute respiratory distress syndrome. Nat Rev Dis Pri, 2019, 5: 18.
9. Fan E, Brodie D, Slutsky AS. Acute respiratory distress syndrome: advances in diagnosis and treatment. JAMA, 2018, 319(7): 698-710.
10. Standiford TJ, Ward PA. Therapeutic targeting of acute lung injury and acute respiratory distress syndrome. Transl Res, 2016, 167(1): 183-191.
11. Shi C, Cao X, Chen X, et al. Intracellular surface-enhanced Raman scattering probes based on TAT peptide-conjugated Au nanostars for distinguishing the differentiation of lung resident mesenchymal stem cells. Biomaterials, 2015, 58: 10-25.
12. Monsel A, Zhu YG, Gudapati V, et al. Mesenchymal stem cell derived secretome and extracellular vesicles for acute lung injury and other inflammatory lung diseases. Expert Opin Biol Ther, 2016, 16(7): 859-871.
13. Zhao R, Su Z, Wu J, et al. Serious adverse events of cell therapy for respiratory diseases: a systematic review and meta-analysis. Oncotarget, 2017, 8(18): 30511-30523.
14. Madl CM, Heilshorn SC, Blau HM. Bioengineering strategies to accelerate stem cell therapeutics. Nature, 2018, 557: 335-342.
15. Qin H, Zhao A. Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics. Protein Cell, 2020: 1-16.
16. Rojas M, Xu J, Woods CR, et al. Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol, 2005, 33(2): 145-152.
17. Barui A, Chowdhury F, Pandit A, et al. Rerouting mesenchymal stem cell trajectory towards epithelial lineage by engineering cellular niche. Biomaterials, 2018, 156: 28-44.
18. Zhao Y, Yang C, Wang H, et al. Therapeutic effects of bone marrow-derived mesenchymal stem cells on pulmonary impact injury complicated with endotoxemia in rats. Int Immunopharmacol, 2013, 15(2): 246-253.
19. Deng HM, Wu LM, Liu MY, et al. Bone Marrow Mesenchymal Stem Cell-Derived Exosomes Attenuate LPS-Induced ARDS by Modulating Macrophage Polarization Through Inhibiting Glycolysis in Macrophages. Shock, 2020.
20. Cai DS, Zhou H, Liu WW, et al. Protective effects of bone marrow-derived endothelial progenitor cells and Houttuynia cordata in lipopolysaccharide-induced acute lung injury in rats. Cell Physiol Biochem, 2013, 32(6): 1577-1586.
21. Xu X, Yang J, Li N, et al. Role of endothelial progenitor cell transplantation in rats with sepsis. Transplant Proc, 2015, 47(10): 2991-3001.
22. Qi Y, Qian L, Sun B, et al. Mobilization of endothelial progenitor cells from bone marrow is impaired in a piglet model of acute respiratory distress syndrome. Pediatr Crit Care Med, 2013, 14: e233-e242.
23. Zhou Y, Li P, Goodwin AJ, et al. Exosomes from endothelial progenitor cells improve outcomes of the lipopolysaccharide-induced acute lung injury. Crit Care, 2019, 23: 44.
24. Abe S, Boyer C, Liu X, et al. Cells derived from the circulation contribute to the repair of lung injury. Am J Respir Crit Care Med, 2004, 170(11): 1158-1163.
25. Zheng G, Huang L, Tong H, et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir Res, 2014, 15(1): 39.
26. Gupta K, Hergrueter A, Owen CA. Adipose-derived stem cells weigh in as novel therapeutics for acute lung injury. Stem Cell Res Ther, 2013, 4(1): 19.
27. Bacakova L, Zarubova J, Travnickova M, et al. Stem cells: their source, potency and use in regenerative therapies with focus on adipose-derived stem cells - a review. Biotechnol Adv, 2018, 36: 1111-1126.
28. Toya SP, Li F, Bonini MG, et al. Interaction of a specific population of human embryonic stem cell-derived progenitor cells with CD11b+ cells ameliorates sepsis-induced lung inflammatory injury. Am J Pathol, 2011, 178(1): 313-324.
29. Sun N, Panetta NJ, Gupta DM, et al. Feeder-free derivation of induced pluripotent stem cells from adult human adipose stem cells. Proc Natl Acad Sci USA, 2009, 106(37): 15720-15725.
30. Zhou Q, Ye X, Sun R, et al. Differentiation of mouse induced pluripotent stem cells into alveolar epithelial cells in vitro for use in vivo. Stem Cells Transl Med, 2014, 3(6): 675-685.
31. 那仁格日勒. 內皮祖細胞治療急性呼吸窘迫綜合癥大鼠中溶血磷脂酸的增效作用及其機理[D].內蒙古大學, 2017.
32. Tavakol DN, Tratwal J, Bonini F, et al. Injectable, scalable 3D tissue-engineered model of marrow hematopoiesis. Biomaterials, 2020, 232: 119665.
33. He HL, Liu L, Chen QH, et al. MSCs modified with ACE2 restore endothelial function following LPS challenge by inhibiting the activation of RAS. J Cell Physiol, 2015, 230(3): 691-701.
34. Xu XP, Huang LL, Hu SL, et al. Genetic modification of mesenchymal stem cells overexpressing angiotensin Ⅱ type 2 receptor increases cell migration to injured lung in LPS-induced acute lung injury mice. Stem Cells Transl Med, 2018, 7(10): 721-730.
35. Fang M, Gao F, Qian LI, et al. Therapeutic effect of human umbilical cord mesenchymal stem cells modified by angiotensin-converting enzyme 2 gene on bleomycin-induced lung fibrosis injury. Mol Med Rep, 2015, 11(4): 2387-2396.
36. Martínezgonzález I, Roca O, Masclans JR, et al. Human mesenchymal stem cells overexpressing the IL-33 antagonist soluble IL-1 receptor-like-1 attenuate endotoxin-induced acute lung injury. Am J Respir Cell Mol Biol, 2013, 49(4): 552-562.
37. Chang Y, Park SH, Huh JW, et al. Intratracheal administration of umbilical cord blood-derived mesenchymal stem cells in a patient with acute respiratory distress syndrome. J Korean Med Sci, 2014, 29(3): 438-440.
38. Galstyan GM, Makarova PM, Parovichnikova EN. Use of mesenchymal stromal stem cells for the treatment of sepsis. Anesteziol Reanimatol, 2015, 60: 59-65.
39. Simonson OE, Mougiakakos D, Heldring N, et al. In vivo effects of mesenchymal stromal cells in two patients with severe acute respiratory distress syndrome. Stem Cells Transl Med, 2015, 4(10): 1199-1213.
40. Wilson JG, Liu KD, Zhuo HJ, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med, 2015, 3(1): 24-32.
41. Matthay MA, Calfee CS, Zhuo H, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med, 2019, 7(2): 154-162.
42. Chen J, Hu C, Chen L, et al. Clinical Study of Mesenchymal Stem Cell Treatment for Acute Respiratory Distress Syndrome Induced by Epidemic Influenza A (H7N9) Infection: A Hint for COVID-19 Treatment. Engineering(Beijing), 2020, Feb 28. doi: 10.1016/j.eng.2020.02.006. Online ahead of print.
43. Atluri S, Manchikanti L, Hirsch JA. Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically ill COVID-19 patients: the case for compassionate use. Pain Physician, 2020, 23: E71-E83.
44. Liang B, Chen J, Li T, et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: a case report. Medicine (Baltimore), 2020, 99: e21429.
45. Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2 mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis, 2020, 11: 216-228.

Previous Article
內質網應激：特發性肺纖維化的潛在治療方向

Chinese Journal of Respiratory and Critical Care Medicine

干細胞治療急性呼吸窘迫綜合征及提高療效的相關研究進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content